ArticlePloS one2011
Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 69 citations in OpenAlex.
- Edaravone offers neuroprotection for acute diabetic stroke patients.Irish journal of medical science · 2016Trial
- Injectable Hierarchical Bioactive Hydrogels with Fibroblast Growth Factor 21/Edaravone/Caffeic Acid Asynchronous Delivery for Treating Parkinson's Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Synthesis and Antioxidant Effects of Edaravone-Loaded MPEG-2000-DSPE Micelles in Rotenone-Induced PC12 Cell Model of Parkinson's Disease.Nanomaterials (Basel, Switzerland) · 2024Article
- Nrf2 Signaling Pathway: a Potential Therapeutic Target in Combating Oxidative Stress and Neurotoxicity in Chemotherapy-Induced Cognitive Impairment.Molecular neurobiology · 2024Review
- Sericin alleviates motor dysfunction by modulating inflammation and TrkB/BDNF signaling pathway in the rotenone-induced Parkinson's disease model.BMC pharmacology & toxicology · 2023Article
- Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection.Antioxidants (Basel, Switzerland) · 2022Review
- Article
- Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis.Pharmaceuticals (Basel, Switzerland) · 2020Review
- The Cataleptic, Asymmetric, Analgesic, and Brain Biochemical Effects of Parkinson's Disease Can Be Affected byBioMed research international · 2020Article
- miR-185 and SEPT5 Genes May Contribute to Parkinson's Disease Pathophysiology.Oxidative medicine and cellular longevity · 2019Article
- Tetramethylpyrazine Ameliorates Rotenone-Induced Parkinson's Disease in Rats: Involvement of Its Anti-Inflammatory and Anti-Apoptotic Actions.Molecular neurobiology · 2017Article
- hVMAT2: A Target of Individualized Medication for Parkinson's Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2016Article
- Mitochondria: A Therapeutic Target for Parkinson's Disease?International journal of molecular sciences · 2015Review
- Melatonin inhibits manganese-induced motor dysfunction and neuronal loss in mice: involvement of oxidative stress and dopaminergic neurodegeneration.Molecular neurobiology · 2015Article
- Protective Effect of Edaravone in Primary Cerebellar Granule Neurons against Iodoacetic Acid-Induced Cell Injury.Oxidative medicine and cellular longevity · 2015Article
- Mitochondria-Targeted Protective Compounds in Parkinson's and Alzheimer's Diseases.Oxidative medicine and cellular longevity · 2015Review
- Neuroprotective effect of edaravone in experimental glaucoma model in rats: a immunofluorescence and biochemical analysis.International journal of ophthalmology · 2015Article
- Edaravone mitigates hexavalent chromium-induced oxidative stress and depletion of antioxidant enzymes while estrogen restores antioxidant enzymes in the rat ovary in F1 offspring.Biology of reproduction · 2014Article
- Inhibitory effects of edaravone in β-amyloid-induced neurotoxicity in rats.BioMed research international · 2014Article
- Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease.Redox biology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
Abstract
3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone), an effective free radical scavenger, provides neuroprotection in stroke models and patients. In this study, we investigated its neuroprotective effects in a chronic rotenone rat model for Parkinson's disease. Here we showed that a five-week treatment with edaravone abolished rotenone's activity to induce catalepsy, damage mitochondria and degenerate dopamine neurons in the midbrain of rotenone-treated rats. This abolishment was attributable at least partly to edaravone's inhibition of rotenone-induced reactive oxygen species production or apoptotic promoter Bax expression and its up-regulation of the vesicular monoamine transporter 2 (VMAT2) expression. Collectively, edaravone may provide novel clinical therapeutics for PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.